alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

32,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 52 studies in Treatments · tagged Diagnosis (page 2 of 3) · 32,180 in the whole library · How the 0–100 score works

Download bibliography of these 52 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 17,651 studies have no institution on record and are not counted here.

What “Treatments” covers

Treatments — Drug and non-drug treatment research — what was tested, in whom, and what changed — plus the approvals and coverage decisions that followed.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Balancing Speed and Sensitivity: Echo-Planar Accelerated MRI for ARIA-H Screening in Anti-Aβ Therapeutics

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Investigative radiology 2026-05-01

The recent advent of anti-amyloid-β monoclonal antibodies has introduced new demands for MRI-based screening of amyloid-related imaging abnormalities, particularly the hemorrhage subtype (ARIA-H). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International journal of geriatric psychiatry 2000-09-01

In several retrospective post-mortem studies, patients meeting clinical criteria for Alzheimer's disease (AD) who gained the greatest cognitive benefit from treatment with an acetylcholinesterase (AChE) inhibitor were found to have neocortical Lewy bodies accompanying classical AD neuropathology. 5 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source

Effect of Individual Virtual Reality Cognitive Training Programs on Cognitive Function and Depression in Middle-Aged Women: Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 44 out of 100. JMIR mental health 2023-10-25

These programs are considered beneficial nonpharmacological cognitive training interventions for middle-aged women at high risk of cognitive impairment. 1 key finding →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Medical clinics of North America 2024-11-19

Alzheimer's disease (AD) is the most common neurodegenerative disorder, and for providers the term AD is often avoided, favoring generic terms like memory loss or dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Diagnosis, pathomechanisms and therapy of cerebral amyloid angiopathy-related inflammation (CAA-ri)

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurological research and practice 2025-04-26

CAA-ri gains increasing interest as a spontaneous human model of iatrogenic edematous amyloid-related imaging abnormalities (ARIA-E) in the context of amyloid-modifying therapies. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

[Precautions for Neurosurgeons in Administering Anti-Amyloid β Antibody Therapy]

✓ Peer-reviewed alzhub usefulness score 41 out of 100. No shinkei geka. Neurological surgery 2025-09-01

In Japan, anti-amyloid β (Aβ) monoclonal antibodies, including lecanemab and donanemab, have recently been approved as disease-modifying therapies for early-stage Alzheimer's disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

✓ Peer-reviewed alzhub usefulness score 36 out of 100. British journal of clinical pharmacology 2012-04-01

Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine. 1 key finding →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source

Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Alzheimer's disease : JAD 2008-03-01

A century of research has passed since the discovery and definition of Alzheimer's disease (AD), the primary common dementing disorder worldwide. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia

✓ Peer-reviewed alzhub usefulness score 36 out of 100. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2008-11-01

Although the available therapies for dementia can help with the management of symptoms, there is a need to develop more effective interventions. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome

✓ Peer-reviewed alzhub usefulness score 28 out of 100. S S Korsakov Journal of Neurology and Psychiatry 2025-08-29

Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetric parkinsonism, dystonia, myoclonia) and cortical disorders (apraxia, disorders of complex types of sensitivity, the alien limb phenomenon). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

REDEFINING ALZHEIMER’S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERS

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Journal of medical & health sciences review. 2025-12-25

This article tells us how modern biotechnology and AI are redefining Alzheimer’s disease through early detection, advanced biomarkers, and innovative treatments like lecanemab. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Feasibility of remote self-administered cognitive assessment in an Alzheimer's disease treatment clinic

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-16

IntroductionRemote cognitive assessments offer an accessible, scalable way to support clinical characterization and longitudinal monitoring of cognition. 3 key findings →

Design: longitudinal study Participants: 209 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events

Last updated